DK3153526T3 - Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler - Google Patents

Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler Download PDF

Info

Publication number
DK3153526T3
DK3153526T3 DK16198909.0T DK16198909T DK3153526T3 DK 3153526 T3 DK3153526 T3 DK 3153526T3 DK 16198909 T DK16198909 T DK 16198909T DK 3153526 T3 DK3153526 T3 DK 3153526T3
Authority
DK
Denmark
Prior art keywords
antibodies
inhibit
activity
human
regulatory cells
Prior art date
Application number
DK16198909.0T
Other languages
English (en)
Inventor
Armand Bensussan
Nathalie Bonnefoy-Berard
Jean-François Eliaou
Yves Levy
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40568778&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3153526(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK3153526T3 publication Critical patent/DK3153526T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DK16198909.0T 2008-01-31 2009-01-30 Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler DK3153526T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08300061 2008-01-31
EP08162683 2008-08-20
EP09705212.0A EP2238170B1 (en) 2008-01-31 2009-01-30 Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity

Publications (1)

Publication Number Publication Date
DK3153526T3 true DK3153526T3 (da) 2020-12-14

Family

ID=40568778

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09705212.0T DK2238170T3 (da) 2008-01-31 2009-01-30 Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler
DK16198909.0T DK3153526T3 (da) 2008-01-31 2009-01-30 Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK09705212.0T DK2238170T3 (da) 2008-01-31 2009-01-30 Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler

Country Status (8)

Country Link
US (3) US20100303828A1 (da)
EP (2) EP2238170B1 (da)
JP (2) JP6018361B2 (da)
DK (2) DK2238170T3 (da)
ES (2) ES2848323T3 (da)
HU (1) HUE032025T2 (da)
PT (1) PT2238170T (da)
WO (1) WO2009095478A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2848323T3 (es) 2008-01-31 2021-08-06 Inst Nat Sante Rech Med Anticuerpos contra CD39 humano y uso de los mismos para inhibir la actividad de las células T reguladoras
US8865653B2 (en) * 2010-04-22 2014-10-21 Institut Gustave Roussy Method of treatment for immunogenic treatment resistant cancer
TWI807362B (zh) 2010-11-30 2023-07-01 日商中外製藥股份有限公司 細胞傷害誘導治療劑
ES2684602T3 (es) * 2010-12-22 2018-10-03 Orega Biotech Anticuerpos contra CD39 humano y uso de los mismos
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
BR112016002199B8 (pt) * 2013-08-01 2024-03-05 Argen X N V Anticorpo que se liga a um complexo de hgarp e tgf-b1 latente, composição compreendendo o mesmo, uso e linhagem celular de hibridoma
RU2722788C2 (ru) 2014-04-07 2020-06-03 Чугаи Сейяку Кабусики Кайся Иммуноактивирующая антигенсвязывающая молекула
CA2947157A1 (en) 2014-05-13 2015-11-19 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
EP3215538A4 (en) * 2014-11-07 2018-07-04 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
JP6154415B2 (ja) * 2015-03-20 2017-06-28 株式会社三共 遊技機
JP6154416B2 (ja) * 2015-03-20 2017-06-28 株式会社三共 遊技機
JP6154417B2 (ja) * 2015-03-20 2017-06-28 株式会社三共 遊技機
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha METHOD FOR ENHANCING THE HUMORAL IMMUNE RESPONSE
CA3005986A1 (en) * 2015-11-23 2017-06-01 Innate Pharma Cd39 vascular isoform targeting agents
WO2017157948A1 (en) 2016-03-14 2017-09-21 Innate Pharma Anti-cd39 antibodies
ES2820173T3 (es) 2016-05-06 2021-04-19 Inst Nat Sante Rech Med Composiciones farmacéuticas para el tratamiento de la leucemia mieloide aguda (LMA) quimiorresistente
KR102531889B1 (ko) 2016-06-20 2023-05-17 키맵 리미티드 항-pd-l1 및 il-2 사이토카인
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
CA3039068A1 (en) * 2016-10-07 2018-04-12 Secarna Pharmaceuticals Gmbh & Co. Kg Immunosuppression-reverting oligonucleotides inhibiting the expression of cd39
US11180554B2 (en) * 2016-12-13 2021-11-23 Astellas Pharma Inc. Anti-human CD73 antibody
EP3558377A1 (en) * 2016-12-23 2019-10-30 Virttu Biologics Limited Treatment of cancer
JP7308150B2 (ja) 2017-03-16 2023-07-13 イナート・ファルマ・ソシエテ・アノニム 癌を処置するための組成物及び方法
PE20200617A1 (es) 2017-07-31 2020-03-11 Tizona Therapeutics Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39
BR112020006809A2 (pt) 2017-10-06 2020-10-06 Innate Pharma anticorpos, agente, uso, composto, composição farmacêutica, kits e composição ou uso
KR20200088811A (ko) 2017-11-15 2020-07-23 이나뜨 파르마 Atp 방출의 효과의 강화
JP6813712B2 (ja) 2017-12-01 2021-01-13 アッヴィ・インコーポレイテッド グルココルチコイド受容体作動薬及びそのイムノコンジュゲート
MX2021015518A (es) 2018-03-14 2022-07-21 Surface Oncology Inc Anticuerpos que se unen a cd39 y sus usos.
CN112839675A (zh) * 2018-06-14 2021-05-25 贝丝以色列女执事医疗中心 通过外切核苷酸酶抑制和抗体介导的靶吞排作用预防或逆转t细胞衰竭的组合物和方法
CN112334486A (zh) 2018-06-18 2021-02-05 先天制药公司 用于治疗癌症的组合物和方法
WO2020115262A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
WO2021037037A1 (en) * 2019-08-27 2021-03-04 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-cd39 antibodies
WO2021055329A1 (en) 2019-09-16 2021-03-25 Surface Oncology, Inc. Anti-cd39 antibody compositions and methods
CN110407941B (zh) * 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途
KR20230019414A (ko) * 2020-04-03 2023-02-08 트리슐라 테라퓨틱스, 인코포레이티드 항-cd39 항체 및 입양 세포 요법을 포함하는 조합 요법
WO2022169825A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023164872A1 (en) * 2022-03-03 2023-09-07 Arcus Biosciences, Inc. Anti-cd39 antibodies and use thereof
US20240034803A1 (en) * 2022-03-03 2024-02-01 Arcus Biosciences, Inc. Anti-cd39 antibodies and use thereof
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0689601B1 (en) 1993-02-22 2006-10-04 The Rockefeller University Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
CA2210620C (en) 1995-01-18 2004-06-22 Boehringer Mannheim Gmbh Anti-cd 30 antibodies preventing proteolytic cleavage and release of membrane-bound cd 30 antigen
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
AU5265296A (en) 1995-04-10 1996-10-30 Universite De Sherbrooke Atp-diphosphohydrolases, process of purification thereof and process of producing thereof by recombinant technology
DE69633973T2 (de) 1995-09-11 2005-12-22 Kyowa Hakko Kogyo Co., Ltd. Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1998045322A2 (en) 1997-04-10 1998-10-15 Royal Netherlands Academy Of Arts And Sciences Diagnosis method and reagents
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2003052121A2 (en) * 2001-12-17 2003-06-26 Beth Israel Deaconess Medical Center Method of reducing angiogenesis
AU2003232456B2 (en) 2002-05-30 2009-06-04 Macrogenics, Inc. CD16A binding proteins and use for the treatment of immune disorders
US20050037382A1 (en) * 2003-04-08 2005-02-17 Robson Simon C. Methods and compositions for treating and preventing autoimmune disorders
US20060002932A1 (en) * 2004-06-04 2006-01-05 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
EP1872126A4 (en) * 2005-04-18 2009-03-25 Metabolex Inc CD39L3 AND ITS ROLE IN DIABETES
WO2006111986A1 (en) * 2005-04-19 2006-10-26 Fondazione Santa Lucia I.R.C.C.S. Method for the detection and the isolation of immunosuppressive regulatory t cells and uses thereof
CN105315373B (zh) 2005-05-09 2018-11-09 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
BRPI0813514A2 (pt) 2007-07-16 2019-09-24 Genentech Inc anticorpos anti-cd79b humanizados e imunoconjugados e métodos de uso
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
ES2848323T3 (es) 2008-01-31 2021-08-06 Inst Nat Sante Rech Med Anticuerpos contra CD39 humano y uso de los mismos para inhibir la actividad de las células T reguladoras
MX2010008786A (es) 2008-02-11 2010-12-01 Curetech Ltd Anticuerpos monoclonales para tratamiento de tumores.
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
SG196798A1 (en) 2008-12-09 2014-02-13 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
CA2778714C (en) 2009-11-24 2018-02-27 Medimmune Limited Targeted binding agents against b7-h1
DK2506871T3 (da) 2009-11-30 2017-01-02 Janssen Biotech Inc ANTISTOF-Fc-MUTANTER MED ABLATEREDE EFFEKTORFUNKTIONER
US8865653B2 (en) 2010-04-22 2014-10-21 Institut Gustave Roussy Method of treatment for immunogenic treatment resistant cancer
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
ES2684602T3 (es) 2010-12-22 2018-10-03 Orega Biotech Anticuerpos contra CD39 humano y uso de los mismos
BR112013018317A2 (pt) 2010-12-23 2017-03-21 Janssen Biotech Inc mutantes de fc do anticorpo resistentes a protease ativa
ES2669310T3 (es) 2011-04-20 2018-05-24 Medimmune, Llc Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
HUE050596T2 (hu) 2014-11-21 2020-12-28 Bristol Myers Squibb Co Antitestek CD73 ellen és azok felhasználásai
CA3005986A1 (en) 2015-11-23 2017-06-01 Innate Pharma Cd39 vascular isoform targeting agents
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
JP7308150B2 (ja) 2017-03-16 2023-07-13 イナート・ファルマ・ソシエテ・アノニム 癌を処置するための組成物及び方法
PE20200617A1 (es) 2017-07-31 2020-03-11 Tizona Therapeutics Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39
BR112020006809A2 (pt) 2017-10-06 2020-10-06 Innate Pharma anticorpos, agente, uso, composto, composição farmacêutica, kits e composição ou uso
KR20200088811A (ko) 2017-11-15 2020-07-23 이나뜨 파르마 Atp 방출의 효과의 강화
CN112334486A (zh) 2018-06-18 2021-02-05 先天制药公司 用于治疗癌症的组合物和方法

Also Published As

Publication number Publication date
EP2238170A1 (en) 2010-10-13
ES2848323T3 (es) 2021-08-06
US10662253B2 (en) 2020-05-26
US20210032367A1 (en) 2021-02-04
EP2238170B1 (en) 2016-11-23
EP3153526B1 (en) 2020-09-23
WO2009095478A1 (en) 2009-08-06
JP6041842B2 (ja) 2016-12-14
JP2011510953A (ja) 2011-04-07
ES2618292T3 (es) 2017-06-21
JP2015057405A (ja) 2015-03-26
US11685792B2 (en) 2023-06-27
US20160137747A1 (en) 2016-05-19
PT2238170T (pt) 2017-02-21
HUE032025T2 (en) 2017-08-28
JP6018361B2 (ja) 2016-11-02
DK2238170T3 (da) 2017-02-27
US20100303828A1 (en) 2010-12-02
EP3153526A1 (en) 2017-04-12

Similar Documents

Publication Publication Date Title
DK3153526T3 (da) Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler
DK3184109T3 (da) Fremgangsmåder til forbedring af natural killer-cellers proliferation og aktivitet
IL287990A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
BRPI0821658A2 (pt) Anticorpos contra nkg2d humano e usos dos mesmos
DK3560915T3 (da) Polypeptider med oxidoreduktaseaktivitet og anvendelser deraf
BRPI1011710A2 (pt) lágrimas artificiais e usos trapêuticos
DK2355670T3 (da) Næringsmiddel indeholdende arabinoxylan og oligosaccharider
DK2411028T3 (da) Terapi til fremme af cellevækst
EP2340031A4 (en) USE OF SFM TRAPS TO INCREASE ERYTHROCYTE RATES
BR112013012190A2 (pt) composições adesivas e seus usos
BRPI0906387A2 (pt) Anticorpos alfa 5 - beta 1 e seus usos
LT2576768T (lt) Gamtinės wharton`s jelly kamieninės ląstelės ir jų gryninimas
DK2268141T3 (da) Forbindelse og fremgangsmåde til at reducere urinsyre
BRPI0923015A2 (pt) enxertos ósseos com atividade de protease reduzida e métodos de seleção e uso
EP2227540A4 (en) DIFFERENTIATION OF HUMAN CELLS
DK2352493T3 (da) Terapeutisk, diætetisk eller kosmetisk anvendelse af forbindelser med specifik antiapoptotisk aktivitet mod caspase-3 og sammensætninger, der indeholder disse forbindelser
DK2342341T3 (da) Forbindelser og fremgangsmåder til at reducere rekruttering og/eller migration af polymorfnukleare celler
DK2293846T3 (da) Depsipeptider og deres terapeutiske anvendelse
DK2523911T3 (da) Bærerindsats til at rumme og opretholde biofilmkulturen af rensningsstrukturer
BR112012000905A2 (pt) emplastro adesivo com enzima
FI20095792A0 (fi) Ihmissolujen käyttö
DK2231173T3 (da) Nutraceutisk præparat og fremgangsmåder til anvendelse
TH125076B (th) องค์ประกอบและวิธีการสำหรับการใช้เซลล์เพื่อการรักษาเนื้อเยื่อหัวใจ
GB201000790D0 (en) The regulation of protein expression through cell binding structures: when and how much; How to get rid of biofilm?
UA18862S (uk) Спинка крісла